Compare 8x8 Inc (EGHT) vs Hims and Hers Health Inc (HIMS) Price & Performance

EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.

Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.